AI Summary
Telix reported Q2 2026 revenue of US$247 million, up 7% QoQ and 21% YoY, led by Precision Medicine. The company reaffirmed FY2026 revenue guidance above US$1 billion, aided by a US$40 million upfront from Regeneron and FDA alignment enabling ProstACT Part 2. Ongoing PSMA imaging and Theranostics expansion could sustain upside into 2027.
Sentiment Rationale
The quarter's strong revenue growth, reaffirmed >$1B guidance, and a $40M upfront from Regeneron improve visibility on cash flow and R&D funding, likely supporting a near-term stock move.
Trading Thesis
Positive quarterly results and strategic partnerships suggest near-term TLX upside, with key milestones to watch in 2H2026.
Market-Moving
- Q2 results and >US$1B FY2026 guidance could spark a TLX rally.
- Regeneron upfront US$40M strengthens TLX’s balance sheet and R&D flexibility.
- FDA ProstACT alignment supports potential U.S. Part 2 progression.
- BiPASS and PSMA imaging milestones may unlock regulatory submissions.
Key Facts
- Group revenue US$247M; QoQ +7%, YoY +21%.
- Precision Medicine revenue US$202M; QoQ +9%, YoY +30%.
- FY2026 revenue guidance >US$1B; includes US$40M Regeneron income.
- FDA alignment on ProstACT Phase 3; Part 2 initiation anticipated.
Companies Mentioned
- Telix Pharmaceuticals Limited (TLX): Reported Q2 2026 results; reaffirmed >US$1B revenue guidance; strategic regulatory and collaboration milestones.
- Regeneron Pharmaceuticals, Inc. (REGN): Strategic collaboration with Telix; US$40M non-refundable upfront payment; potential for multiple future programs.
Earnings
Earnings with accompanying Corporate Developments due to Regeneron deal and financing actions; reflectsTLX’s growth trajectory in both Diagnostics and Therapeutics.